Connect with us
Advertise With Us


HIV Prevention: Injectable Drug More Effective Than Daily Pill – Scientists



Researchers have revealed that a single shot every two months prevents HIV better than the most commonly used daily pill.

According to the New York Times, at the moment, Truvada and Descovy, made by Gilead Sciences, are the only drugs approved by the Food and Drug Administration for prevention of HIV infection, a strategy called PrEP.

The NYT reports that Gilead has heavily been criticized for setting a

high price for the pills, adding that many people are unable or  unwilling to take a daily pill to prevent HIV infection, particularly

in low-income countries where the coronavirus pandemic is disrupting  services and access to antiretroviral drugs.

“The randomized, double-blind trial of the drug, called cabotegravir,  was conducted by the HIV Prevention Trials Network, a scientific  collaborative. The trial included nearly 4,600 cisgender men and transgender women who have sex with men and was conducted at 43 sites  in seven countries.

“Each of the participants got a shot every two months, either

cabotegravir or a placebo. Each participant also took either Truvada  or a placebo pill every day. (A separate study of cisgender women in  sub-Saharan Africa was designed at the same time, but it has taken  longer to enroll participants.)

“The trial was expected to continue well into 2022, but it was stopped  in May after an interim analysis showed that cabotegravir was highly  effective.

“In the final analysis, 13 participants who got the injections every eight weeks were infected with HIV, compared with 39 who were infected  among those who took the daily pill. The shot was 66 percent more  effective than Truvada.”